Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
565 participants
OBSERVATIONAL
2021-03-22
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Individualizing Surveillance Mammography for Older Breast Cancer Survivors
NCT03865654
Post-Treatment Surveillance in Breast Cancer: Bringing CER to the Alliance
NCT02171078
Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
NCT05326295
Health Status of Women With Breast Cancer
NCT03761940
Satisfaction Survey for the Outpatient Unit Dedicated to Post-cancer Treatment
NCT05530824
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The effectiveness evaluation of patient/clinician acceptance, feasibility, patient benefits/satisfaction will be performed using a non-randomised 'Before-After study' approach, followed by immediate implementation in practice for faster patient benefits.
Main outcomes measured will include:
1. Patient-Reported Outcomes questionnaires: quality of life, symptom control, and self-efficacy.
2. Clinical measures: number of hospital contacts, recurrence rates.
3. Process measures: survivors compliance with self-reports, clinical tests attendance; using online self-management resources.
The project will be structured in four phases:
PHASE 1 (Months 0-12): Develop the content of the surveillance toolkits for breast and bowel (colorectal) cancers and setup on the electronic system. This will include the selection of cancer-specific symptoms for patient self-reporting, collating the existing evidence on side-effects management and the development of patient advice corresponding to severity levels. Once the two toolkits for breast and bowel (colorectal) cancers are completed, they will be set up on the electronic system. Printed booklets can also be produced from these.
Recruitment methods:
Cancer survivors and caregivers will be invited from outpatient surveillance clinics or by telephone by the cancer team if discharged recently from secondary care, and by public advertising for breast and colorectal cancer survivors volunteers. Purposive sampling will represent a variety of age groups, cancer recurrence risk, time post treatment, socio-economic background, expecting a sample of 8-10 survivors/carers per cancer site. Participants will be invited for an interview conducted over the telephone or at St James's Hospital.
Healthcare professionals (HCP) involved in breast and colorectal cancer care at St James's Hospital will also be invited to participate in interviews. This is done face to face at the hospital followed up by a phone call or an individual email depending on the previous conversations had between the researchers and the HCP.
Interviews will be transcribed verbatim and subjected to thematic content analysis.
Phase 1 Objectives:
1. Select questions for self-reporting
2. Determine severity thresholds
3. Determine content of the self-management guidance
4. Describe the current usual care after treatment by cancer type and how to modify it to incorporate remote surveillance
5. Identify potential improvements to the electronic system.
PHASE 2:"Before study" (Months 6-30; 12-months recruitment,12-months follow-up)The before study will be a structured audit of current practice, running in parallel with Phase 1.
Participants who consent will complete outcome measures at baseline, 3, 6 and 2 months on paper. Demographic data will be collected after consent and clinical data will be collected via the EPR.
Recruitment methods:
The study will include recruitment over 12 months of all consecutive eligible patients with a follow-up of 12 months. The estimated numbers are 120 new bowel (colorectal) cancer patients per year and 300 breast cancer patients. The study anticipates 70% consent rate, giving approximately 85 bowel (colorectal) and 210 breast cancer participants.
Phase 2 Objectives:
1. Establish data on current practice using clinical and patient outcomes and best methods for collecting them
2. Provide 'Before' data to compare to "After study" to estimate the effects of the new intervention
3. Establish prospectively what proportion of eligible patients would consent to a remote monitoring study.
PHASE 3:"After study"(Months 18-42;12-months recruitment, 12-months follow-up) Participants will be completing the intervention for 12 months. The 'After study' will start when Phase 1 is completed, including a successful usability testing.
Participants who consent will complete outcomes measures at baseline, 3, 6 and 12 months on paper (same as Phase 2). In addition, they will also complete the intervention: online symptom reporting questionnaire.
Demographic data will be collected after consent and clinical data via the Electronic patient records (EPR).
Recruitment methods:
Based on current experience of other studies conducted 15% of breast and 20% of bowel (colorectal) patients will not use online resources. Therefore, the estimated number of full participants will be about 170 in breast and 70 in bowel (colorectal) cancer clinics. The remote monitoring will only be available to participants classed as being moderate to lower risk by their clinical team. The intervention is an additional service for patients conducted along side their standard cancer care.
Phase 3 Objectives:
1. Assess the effects of the intervention in terms of participants' quality of life at baseline, 3, 6 and 12 months
2. Examine survivors' engagement with the intervention - acceptability, feasibility and use of the online system and respective advice
3. Examine clinicians' engagement
Secondary objectives:
4. Monitor the safety i.e. diagnoses of recurrences and psychological morbidity, how were those detected
5. Evaluate impact on participants' self-efficacy in managing cancer consequences and fear of recurrence
6. Evaluate participants' satisfaction with care
7. Compare use of National Health Service (NHS) resources in Before and After phase.
The implementation of the intervention:
The intervention (as developed in Phase 1) will be implemented following the relevant staff and participant training. The frequency of participants' completions will be determined in Phase 1. Participants will be asked to complete the online symptom monitoring from home, with the possibility to complete the questions more often, if they experience any symptoms they may wish to report. Text message or email reminders will be sent to the participants (based on their preferred contact method) as a prompt to complete the online monitoring symptom questions, and where relevant to attend for the blood tests or surveillance scans.
Providers are expected to review and respond to any notifications for significant symptoms, in line with the agreed thresholds and are expected to review the self-reports during the clinic visits, discuss them with the patient and take any actions, as appropriate.
Participants and staff interviews will be conducted during and at the end of Phase 3.
PHASE 4: (starting month 30, with specific launch activities 42-48): Roll-out and implementation in practice. Following the principles of the Action research model (Act phase), the aim is to start roll-out immediately after completion of the 12-month recruitment in the "After" study. This will involve further work to apply the learning from Phase 3:
1. Simplify patient approach and consent to integrate it into the routine clinics flow
2. Identify appropriate clinic staff to approach patients
3. Modify, if needed, the self-reported questions, the thresholds or the content of the advice.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Breast Cancer Participants-Before Phase
Breast cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time.
No interventions assigned to this group
Colorectal (bowel) Cancer Participants-Before Phase
Colorectal cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time.
No interventions assigned to this group
Breast Cancer Participants-After Phase
Breast cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time. In addition they will also complete an online symptom report from home with self-management advice (frequency of completion to be determined in phase 2)
Online symptom reporting
Online symptom reporting questionnaire with linked self-management advice
Colorectal (bowel) Cancer Participants-After Phase
Colorectal cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time. In addition they will also complete an online symptom report from home with self-management advice (frequency of completion to be determined in phase 2)
Online symptom reporting
Online symptom reporting questionnaire with linked self-management advice
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Online symptom reporting
Online symptom reporting questionnaire with linked self-management advice
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Participating patients Phases 1 and 2:
* Patients (aged 16 years or over) attending St James' University Hospital Bexley Wing, with breast and/or colorectal cancer in remission, completed their cancer treatment.
* Able and willing to give informed consent
* Able to read and understand English
Participating patients Phase 3:
* Patients (aged 16 years or over) attending St James' University Hospital Bexley Wing, with breast and/or bowel (colorectal) cancer in remission, completed their cancer treatment.
* Able and willing to give informed consent
* Able to read and understand English
* Access to the internet
Exclusion Criteria
* Patients exhibiting overt psychopathology/cognitive dysfunction
* Patients taking part in other clinical trials involving the completion of extensive patient reported outcome or quality of life measures
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Leeds
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Galina Velikova
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Galina Velikova
Role: PRINCIPAL_INVESTIGATOR
University of Leeds
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Leeds Teaching Hospitals NHS Trust
Leeds, West Yorkshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
L424
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.